A September 29 opinion piece published in The Washington Post from PhRMA
President and CEO Steve Ubl is a classic rerun of Big Pharma’s deflection
playbook, filled with empty promises and grand pledges meant to deflect
responsibility and dodge accountability for high prescription drug prices.





 



SECOND OPINION: BIG PHARMA’S RHETORIC OF DEFLECTION DOESN’T ADDRESS CAUSE OF
HIGH PRESCRIPTION DRUG PRICES

PhRMA Continues to Dodge Responsibility for Egregious Pricing Practices and
Anti-Competitive Tactics



A September 29 opinion piece
<[link removed]>
published in The Washington Post from PhRMA President and CEO Steve Ubl is a
classic rerun of Big Pharma’s deflection playbook, filled with empty promises
and grand pledges meant to deflect responsibility and dodge accountability for
high prescription drug prices.



PhRMA, of course, does not acknowledge rapidly rising launch prices being set
by brand name manufacturers on new products, years of egregious and unjustified
price hikes outpacing inflation, especially on blockbuster medications, or the
litany of anti-competitive tactics deployed by Big Pharma to undermine
competition from more affordable generics and biosimilars.



Instead, PhRMA falls back on its usual finger-pointing at others in the drug
supply chain, with claims about the industry’s commitment to the American
people they continue to price-gouge thrown in.



The fact is that brand name drug companies continue to shelter profits
overseas to avoid paying U.S. taxes. As documented by a U.S. Senate Committee
on Financeinvestigation
<[link removed]>
earlier this year, companies like Pfizer have perfected “round-tripping” tax
avoidance schemes, shifting profits from U.S. sales into foreign subsidiaries.
This accounting trick allows pharmaceutical companies to avoid paying billions
in federal income tax by treating sales to U.S. customers as foreign income.
U.S. Senator and Ranking Member Ron Wyden (D-OR) described Pfizer’s move as
“what could be the largest tax-dodging scheme in the history of Big Pharma.”
Other Big Pharma giants cited for similar practices include Merck, AbbVie and
Amgen.



Delivering effective, lasting relief for American patients from out-of-control
prescription drug prices must hold Big Pharma accountable.



Large pharmaceutical companies set increasingly outrageous launch prices on
new medications when they face no competition in the market and have the
greatest possible remaining periods of exclusivity – which are routinely
extended through abuse of the U.S. patent system. According to a Reutersanalysis

<[link removed]>
, launch prices for prescription drugs first entering the market in the United
States more than doubled last year compared to 2021.



Brand name drug companies also continue to hike prescription drug prices at
rates outpacing inflation. A 2024report
<[link removed]>
from AARP found Big Pharma “consistently” increased prices above the rate of
inflation between 2006 and 2020. In fact, the report found that Big Pharma
increased prices on 943 blockbuster drugs widely used by patients faster than
the rate of inflation “in all but one year between 2006 and 2020.”



Big Pharma has not changed that trend. In just the opening days of 2025, Big
Pharma hiked prices on250 medications
<[link removed]>
, with a median increase of 4.5 percent, exceeding the2.7 percent
<[link removed]> rate of inflation
from the U.S. Bureau of Labor Statistics at the time.



Big Pharma has a long history of price-gouging American patients through
tactics designed to game the U.S. patent system and block competition from more
affordable alternatives – enabling pharmaceutical manufacturers to maintain
monopolies over their biggest money-makers. Big Pharma companies often file
many, even dozens or hundreds, of patents on a single medication, a practice
known as patent thicketing, to extend exclusivity and block competition from
more affordable options, for months, years and even decades.



According to a study
<[link removed]>
recently published in JAMA Health Forum, lost competition due to Big Pharma’s
patent thickets on just four widely prescribed brand name drugs cost patients,
taxpayers and the U.S. health care system more than $3.5 billion in excess
spending over two years.



Big Pharma’s rhetoric does nothing to take true accountability for the root
cause of high prescription drug prices. Delivering lower prescription drug
prices for the American people must start with lowering the prices set by Big
Pharma.



Read more on Big Pharma’s tax-dodging HERE
<[link removed]>
.



Read more on how Big Pharma’s launch prices have more than doubled since 2021
HERE
<[link removed]>
.



Read more on how Big Pharma’s patent thickets on just four widely prescribed
brand name drugs cost patients, taxpayers and the U.S. health care system $3.5
billionHERE
<[link removed]>
.



Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>